Compare Beyond Meat Inc (BYND) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Gilead Sciences, Inc. — how do they compare? Beyond Meat Inc trades at $0.62 (market cap $320.23M), while Gilead Sciences, Inc. trades at $129.81 (market cap $161.45B). The key difference: Gilead Sciences, Inc. is far larger — about 504.2× Beyond Meat Inc's market cap, and Gilead Sciences, Inc. pays a 2.52% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| BYND | GILD | |
|---|---|---|
Market Cap | $320.23M | $161.45B |
Sector | Consumer Staples | Health |
52-Week High | $4.28 | $155.80 |
52-Week Low | $0.52 | $108.22 |
Enterprise Value | $630.23M | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.63, down 4.15% today, reflecting persistent bearish sentiment amid declining revenues and negative cash flow from operations. The stock shows technical weakness with moving averages signaling bearish momentum, though oversold RSI conditions suggest potential for near-term bounce. Recent earnings show mixed results with Q1 2026 beating expectations but Q4 2025 and Q3 2025 missing estimates. The company continues expansion efforts with new product launches including Beyond Steak Filet and protein beverages.
Investment outlook remains challenging with 57% analyst sell ratings and negative operating cash flow of $145M in 2025. While valuation metrics appear attractive with P/S of 0.65 and EV/EBITDA of 2.08, ongoing revenue declines and reliance on financing activities for liquidity pose significant risks. The turnaround strategy through product diversification faces execution challenges in a competitive plant-based protein market.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
